Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study is currently recruiting patients.
Sponsored by: | Arthur G. James Cancer Hospital & Richard J. Solove Research Institute |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Valproic acid may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Combining decitabine with valproic acid may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of combining decitabine with valproic acid in treating patients who have refractory or relapsed acute myeloid leukemia or previously-treated chronic lymphocytic leukemia or small lymphocytic leukemia.
Condition | Treatment or Intervention | Phase |
---|---|---|
adult acute myeloid leukemia refractory chronic lymphocytic leukemia Small Lymphocytic Lymphoma |
Drug: decitabine Drug: valproic acid Procedure: chemotherapy Procedure: enzyme inhibitor therapy |
Phase I |
MedlinePlus related topics: Bone Marrow Diseases; Immune System and Disorders; Leukemia, Adult Acute; Leukemia, Adult Chronic; Leukemia, Childhood; Lymphatic Diseases; Lymphoma
Study Type: Interventional
Study Design: Treatment
Official Title: Phase I Study of Decitabine and Valproic Acid in Patients With Refractory or Relapsed Acute Myeloid Leukemia or With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
OBJECTIVES: Primary
Secondary
OUTLINE: This is a dose-escalation study. Patients are stratified according to disease (refractory or relapsed acute myeloid leukemia vs chronic lymphocytic leukemia or small lymphocytic lymphoma).
Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days.
Cohorts of 6 patients receive escalating doses of decitabine until the minimally effective pharmacological dose (MEPD) is determined. The MEPD is defined as the dose at which at least 5 of 6 patients meet gene methylation criteria and no more than 1 of 6 patients experiences dose limiting toxicity (DLT).
Once the MEPD is determined, patients receive decitabine at that dose level administered as above and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days.
Cohorts of 3-6 patients receive escalating doses of valproic acid until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. The MEPD of valproic acid is then determined using established gene methylation and toxicity criteria.
Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 84 patients (42 per stratum) will accrued for this study.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |